Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Oppenheimer cut their FY2023 earnings per share estimates for shares of Aurinia Pharmaceuticals in a report issued on Wednesday, December 4th. Oppenheimer analyst J. Kim now forecasts that the company will post earnings of $0.99 per share for the year, down from their previous forecast of $1.12.
Other equities research analysts have also issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, October 17th. Bloom Burton restated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd.
In other news, Senior Officer Bradley Dickerson bought 5,000 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were purchased at an average price of C$5.11 per share, for a total transaction of C$25,542.00. Following the completion of the acquisition, the insider now owns 15,000 shares of the company’s stock, valued at C$76,626. In the last three months, insiders have bought 9,550 shares of company stock valued at $53,567.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.